This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive emricasan 50 mg BID, emricasan 5 mg BID or placebo BID.